CHA Biotech announced on the 19th that it has signed a memorandum of understanding (MOU) with Sartorius Korea Biotech to collaborate on the global development and commercialization of therapeutics.
Sartorius is a leading global corporation headquartered in Germany, specializing in the field of cell manufacturing and cultivation. Mesenchymal stem cells are adult stem cells obtained from tissues such as umbilical cords, bone marrow, and fat.
This MOU outlines that the two companies will work together to establish Korea's first mesenchymal stem cell platform and develop a 50-liter or larger 3D automated mass production process.
The two companies plan to secure mass production technology essential for the development and commercialization of stem cell therapeutics. They will promote the establishment of a stem cell line platform, process automation, joint development of standardized production processes, and the establishment of a mass production platform for next-generation stem cell therapeutics with introduced therapeutic genes.
CHA Biotech has established a full-cycle research and development system in cooperation with CHA Medical Center and CHA Medical Institute. It is also building a production platform for next-generation stem cell therapeutics aimed at the development of treatments for ovarian dysfunction and knee cartilage defects, as well as global market entry. Sartorius plays a role in enhancing stability and efficiency with world-class technology in cell manufacturing and cultivation equipment and media development.
Nam Soo-yeon, head of R&D at CHA Biotech, stated, "Through collaboration with Sartorius, we can solve the technical challenges of mass production of stem cell therapeutics and accelerate the development of therapeutics with international competitiveness."
Kim Deok-sang, CEO of Sartorius, noted, "By combining CHA Biotech's unique stem cell research capabilities with Sartorius' process technology, we will create significant synergies."